146 related articles for article (PubMed ID: 37245298)
1. First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study.
Ye Z; Zhang Y; Chen J; Wang X; Hong Y; Zhao Q
Int Immunopharmacol; 2023 Jul; 120():110344. PubMed ID: 37245298
[TBL] [Abstract][Full Text] [Related]
2. Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study.
Zhang Y; Wang X; Li Y; Hong Y; Zhao Q; Ye Z
Front Immunol; 2023; 14():1141148. PubMed ID: 37033935
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy.
Deng M; Li S; Wang Q; Zhao R; Zou J; Lin W; Mei J; Wei W; Guo R
Ann Med; 2022 Dec; 54(1):803-811. PubMed ID: 35272564
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study.
Ning Z; Xie L; Yan X; Hua Y; Shi W; Lin J; Xu L; Meng Z
Br J Radiol; 2023 Oct; 96(1150):20230079. PubMed ID: 37660471
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
Zhu M; Jin M; Zhao X; Shen S; Chen Y; Xiao H; Wei G; He Q; Li B; Peng Z
BMC Med; 2024 Apr; 22(1):165. PubMed ID: 38637772
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
Luo X; Jia W; Huang Z; Li X; Xing B; Jiang X; Li J; Si A; Yang T; Gao C; Lau WY; Shen F
Oncotarget; 2017 Mar; 8(10):17246-17257. PubMed ID: 27783997
[TBL] [Abstract][Full Text] [Related]
10. Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
Chao J; Wang S; Wang H; Zhang N; Wang Y; Yang X; Zhu C; Ning C; Zhang X; Xue J; Zhang L; Piao M; Wang M; Yang X; Lu L; Zhao H
Cancer Immunol Immunother; 2023 Nov; 72(11):3717-3726. PubMed ID: 37787790
[TBL] [Abstract][Full Text] [Related]
11. Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma.
Lei Z; Ma W; Si A; Zhang Y; Yang F; Yu Q; Tang H; Xiao Q; Zhou J; Wang K; Tang Y; Han T; Yin G; Chen J; Liu X; Zhao H; Yu D; Luo T; Wang Q; Yan M; Mao X; Li J; Wang K; Li J; Zeng Y; Ding D; Chen T; Wu X; Xia Y; Wang K; Guo W; Zhu G; Gao S; Hüser N; Lau WY; Song T; Cheng S; Shen F; Cheng Z
Aliment Pharmacol Ther; 2023 Sep; 58(6):611-622. PubMed ID: 37349908
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
Xu J; Zhang H; Zhang L; Chu X; Li Y; Li G; Nie C; Wang M; Guo Y
Cancer Med; 2023 Dec; 12(23):21159-21171. PubMed ID: 37935113
[TBL] [Abstract][Full Text] [Related]
14. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Shi GM; Huang XY; Wu D; Sun HC; Liang F; Ji Y; Chen Y; Yang GH; Lu JC; Meng XL; Wang XY; Sun L; Ge NL; Huang XW; Qiu SJ; Yang XR; Gao Q; He YF; Xu Y; Sun J; Ren ZG; Fan J; Zhou J
Signal Transduct Target Ther; 2023 Mar; 8(1):106. PubMed ID: 36928584
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer.
Zhu C; Xue J; Wang Y; Wang S; Zhang N; Wang Y; Zhang L; Yang X; Long J; Yang X; Sang X; Zhao H
Front Immunol; 2023; 14():1109292. PubMed ID: 36742297
[TBL] [Abstract][Full Text] [Related]
17. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
Huang Y; Du Z; Kan A; He M; Li H; Lai Z; Wen D; Huang L; Li Q; Xu L; Shi M
Front Immunol; 2024; 15():1260191. PubMed ID: 38384459
[TBL] [Abstract][Full Text] [Related]
19. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
Front Immunol; 2022; 13():931429. PubMed ID: 36248782
[TBL] [Abstract][Full Text] [Related]
20. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Shroff RT; Yarchoan M; O'Connor A; Gallagher D; Zahurak ML; Rosner G; Ohaji C; Sartorius-Mergenthaler S; Parkinson R; Subbiah V; Zinner R; Azad NS
Br J Cancer; 2017 May; 116(11):1402-1407. PubMed ID: 28441383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
